Brent is co-founder and CEO of Specific Biologics, a discovery stage company developing gene editing technologies for therapeutic use. Prior to Specific Biologics, Brent worked for 7 years in the biotechnology industry in various capacities, most recently in business development for a biologics development and manufacturing organization. He started his career in the life sciences as a Ph.D. graduate of Western University’s biochemistry program and completed his MBA at the Richard Ivey School of Business.
Specific Biologics is developing a platform gene editing technology for potential therapeutics. Dualase is designed to overcome two problems with existing gene editing technologies – random DNA insertions / deletions and low frequency of DNA repair. Dualase cuts DNA twice leaving non-compatible ends which creates precision length deletions to disrupt genes or increases the frequency of repair to correct genes.